Story
The Full Story
For five years the story was the same: Cooper is a two-pillar medical-device compounder — contact lenses (CVI) and women's health/fertility (CSI) — levering up to buy growth and riding a post-COVID rebound to double-digit organic growth. That narrative survived through fiscal 2024, then quietly changed in 2025. Organic growth stepped down from 8% to 4%, management stopped celebrating "double-digit" and started celebrating "eight consecutive earnings beats," CSI fertility decelerated sharply, and the company executed a $89M reorganization that was never pre-announced and yielded only a $50M/yr save. Credibility on EPS remained strong throughout; credibility on revenue has softened.
1. The Narrative Arc
The interesting inflection is fiscal 2025, not fiscal 2022. The Generate + Cook acquisitions in 2022 were continuity — Cooper has been a serial acquirer for decades. What broke the pattern was fiscal 2025, when the M&A story stopped being the answer to every question and the story became about cost structure, cash generation, and share count.
2. What Management Emphasized — and Then Stopped Emphasizing
Catalog Error: Table with name themes does not exist!
Did you mean "pg_tables"?
LINE 2: ...'FY2022' as fy, 2022 as yr_sort, theme, fy22 as intensity from themes union all
^What got louder. Free cash flow moved from a routine reconciliation line in fiscal 2022 to the headline metric by fiscal 2026. Cooper never issued explicit annual FCF guidance before FY2026 — the initial FY26 guide of $575-625M plus a three-year $2.2B FCF commitment is a new contract with investors. Share repurchases, dormant from 2017 through 2024 (only ~$78M in FY22, zero in FY23-FY24), jumped to $290M in FY25 and the authorization was tripled to $2B in September 2025.
What got quieter. "Nine consecutive quarters of double-digit organic revenue growth" (Q2 FY23) and "tenth consecutive quarter of double-digit fertility growth" (Q2 FY23) were signature talking points for two years. By FY2025 they had disappeared from the script. Fertility grew 1% in Q4 FY25 and 3% in Q1 FY26 — the streak broke and management never acknowledged it. The Cook Medical acquisition, which cost a $45M termination accrual in 2Q23, was eventually completed (referenced as acquired in FY24 reconciliations) but was never celebrated as the strategic prize it was originally framed as.
3. Risk Evolution
The most visible pivot is tariffs. In FY2021-FY2024 tariffs were a single bullet inside the boilerplate international-operations risk. In fiscal 2025 tariffs became a standalone risk factor with its own heading — "Economic and trade sanctions, including tariff and import/export regulations… could make it more difficult or costly" — and in Q1 FY26 Cooper explicitly called out that gross margin would have been flat "excluding the impact of tariffs." This is not foreshadowing; this is a live P&L issue.
Newly visible: inflation gets its own heading for the first time in FY2022 and persists. Quietly dropped: Brexit (material in FY21, gone by FY23); COVID-19 (dominant in FY21-22, gone by FY24). Escalating steadily: cybersecurity, EU MDR/IVDR compliance, customer consolidation — the last is especially relevant as the consolidation of optical retail chains and fertility clinic networks changes the bargaining structure of both businesses.
4. How They Handled Bad News
Cooper's bad-news handling style is consistent: soften it with a forward bridge, never dwell on the cause, and raise something else to distract. Two episodes stand out.
Episode 1 — Cook Medical termination (Q2 FY2023)
Cooper accrued $45M in Q2 FY2023 for "probable payment of a termination fee" on the Cook Medical Reproductive Health deal originally signed February 2022. Rather than explain what went wrong, the press release buried the accrual in footnote B of the reconciliation table and pivoted the CEO quote to the "ninth consecutive quarter of double-digit" CVI growth. The deal ultimately did close (it reappears as an acquired business in FY2024 reconciliations), meaning Cooper paid a termination fee and completed the acquisition — a fact never spelled out in plain language in any press release we can find. The SightGlass Vision joint-venture deconsolidation a quarter earlier (FY22) followed the same pattern: framed as a $56.9M gain, not as a walk-back from a standalone myopia-spectacle strategy.
Episode 2 — The FY2025 organic growth reset
FY2025 guidance was initiated at 6-8% organic revenue growth in Q4 FY2024, walked down to 5-6% after Q2 FY25, then to 4-4.5% after Q3 FY25. Actual FY25 organic growth was 4%. The explanation evolved in lockstep without acknowledging the pattern:
The pattern is consistent: revenue misses are absorbed quietly, EPS is protected through expense leverage and reorganization, and the forward narrative moves on. No CEO or CFO change followed. No acquisition was blamed by name.
5. Guidance Track Record
Three findings.
EPS delivery is reliable. FY23 landed at the initial midpoint ($12.81 non-GAAP EPS, pre-split). FY24 beat by 7% on a post-split basis ($3.69 actual vs $3.45 initial midpoint). FY25 beat by 4% despite the revenue miss ($4.13 vs $3.97 initial). Cooper has now delivered eight consecutive quarters of non-GAAP EPS beats — a claim management made explicitly in the Q4 FY25 release.
Revenue delivery has degraded. FY23 beat the initial guide by 1.5%. FY24 beat by 1.3%. FY25 missed the initial midpoint by 0.7% — a small miss in absolute terms but a large miss against organic growth expectations (guided 6-8%, delivered 4%). FY25 is the first revenue miss in the observable window and it came without prior warning — initial guide was held through Q1 FY25 and only started coming down in Q2 FY25.
The walk-down pattern matters. Management's language in Q2 and Q3 FY25 emphasized raising EPS guidance while revenue was being trimmed — a useful distraction that worked against consensus but not against the initial annual guide. This is the first fiscal year in the observable window where guidance was revised down on a measure that matters.
Credibility Score (1-10)
Credibility score: 7/10, trending down from 8. EPS delivery, cash flow, and share-repurchase execution are strong. Revenue guidance is no longer dependable as a single-point estimate — ranges have widened, mid-year revisions are larger, and the gap between "double-digit organic" talk and mid-single-digit delivery has opened up. Management has not explicitly reset long-term revenue expectations; until they do, investors should treat annual revenue guides as aspirational and EPS guides as closer to commitments.
6. What the Story Is Now
Cooper in 2026 is no longer a "high-single to low-double-digit organic compounder levering up for tuck-ins." It is a mid-single-digit organic grower with a cash-return pivot underway. The FY26 guide of 4.5-5.5% organic revenue, $4.58-$4.66 non-GAAP EPS, and $600-625M free cash flow — backed by a three-year $2.2B FCF objective and a $2B repurchase authorization — is a materially different investor contract than the one that existed through fiscal 2024.
De-risked:
- EPS delivery mechanics (eight straight beats)
- Debt trajectory (long-term debt down ~$600M year-over-year post Q1 FY26; refinanced to short-term)
- MiSight myopia franchise (FDA, China NMPA, Japan MHLW approvals now in hand; Q4 FY25 up 37%)
- Capital-return credibility (share count down ~5M in FY25, first meaningful buyback since 2017)
Still stretched:
- CSI fertility growth (was 10+% for a decade, printed 1-3% in recent quarters; management calls FY26 "a much stronger year" with no specific catalyst named)
- Tariff pass-through (already a headwind to Q1 FY26 gross margin; exposure to Costa Rica, Hungary, UK manufacturing is geographically concentrated)
- The $50M/yr reorganization save on a $89M one-time charge (17-month payback is fine; but the reorg was reactive, not pre-announced, raising the question of what else is being quietly restructured)
- Revenue guidance credibility (one miss is an event; two would be a pattern)
Believe vs discount. Believe the cash-generation commitment — the FCF guide is new, specific, and tied to explicit debt paydown and repurchase actions that can be checked every quarter. Discount the "double-digit growth is back" framing if it returns in any CEO quote in FY26 — the five-year evidence says Cooper's underlying growth rate has stepped down to mid-single digits, and the FY26 guide of 4.5-5.5% organic implicitly confirms that. The reset is real; the question is whether management is ready to say so in plain language.